drug · small molecule
seralutinib
Phase 3updated 5mo agoby $GOSS Gossamer Bio, Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.
targets
Platelet-derived growth factor receptorMacrophage colony-stimulating factor 1 receptorMast/stem cell growth factor receptor Kit
all catalysts(0)
nothing on the calendar yet
Trials studying seralutinib
- phase3Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- phase3Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- phase2Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
- phase3Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase2GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
News(4)
- Novo workforce down 13,000Follow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 5d ago
- Gossamer regains rights to lung disease asset from Chiesi after Phase 3 failDespite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.biospace · 2mo ago
- After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaborationAfter signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…fiercebiotech · 2mo ago
- Fierce Biotech Layoff Tracker 2026: BMS slashes 265 HQ roles; Novo reveals 4k more employees were laid offAs always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 9mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that